Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
Open Access
Abstract
Objectives: To determine maternal and neonatal specific antibody levels to selected vaccine-preventable infections (pertussis, Haemophilus influenzae type b (Hib), tetanus and pneumococcus). Design: Prospective cohort study. Setting: A UK secondary care maternity unit (March 2011–January 2012). Participants: Mothers and infants within 72 h of delivery were eligible. Unwell individuals, mothers less than 18 years of age, and infants born at less than 36 weeks gestation, or weighing less than 2500 g, were excluded. HIV-infected mothers were included. 112 mother–infant pairs were recruited. Samples from 111 mothers and 109 infants (108 pairs) were available for analysis. Outcome measures: Specific antibody levels were determined using standard commercial ELISAs. Specific antibody to pertussis antigens (PT and FHA) of >50 IU/ml, defined as ‘positive’ by the test manufacturer, were interpreted as protective. Antitetanus antibody titres >0.1 IU/ml and anti-Hib antibody titres >1 mg/l were regarded as protective. Results: Only 17% (19/111) of women exhibited a protective antibody response against pertussis. 50% (56/111) of women had levels of antibody protective against Hib and 79% (88/111) against tetanus. There was a strong positive correlation between maternal-specific and infant-specific antibodies’ responses against pertussis (r s =0.71, ps =0.80, ps =0.90, ps =0.85, p<0.001). Only 30% (33/109) and 42% (46/109) of infants showed a protective antibody response to pertussis and Hib, respectively. Placental transfer (infant:mother ratio) of specific IgG to pertussis, Hib, pneumococcus and tetanus was significantly reduced from HIV-infected mothers to their HIV-exposed, uninfected infants (n=12 pairs) compared with HIV-uninfected mothers with HIV-unexposed infants (n=96 pairs) by 58% (<0.001), 61% (<0.001), 28% (p=0.034) and 32% (p=0.035), respectively. Conclusions: Low baseline antibody levels against pertussis in this cohort suggest the recently implemented UK maternal pertussis immunisation programme has potential to be effective.Keywords
This publication has 45 references indexed in Scilit:
- Can infants be protected by means of maternal vaccination?Clinical Microbiology and Infection, 2012
- IgG Placental Transfer in Healthy and Pathological PregnanciesJournal of Immunology Research, 2011
- Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort studyThe Lancet Infectious Diseases, 2011
- Mother–infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccinationVaccine, 2011
- Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional StudyPLOS Medicine, 2011
- Maternal immunization with tetanus–diphtheria–pertussis vaccine: effect on maternal and neonatal serum antibody levelsAmerican Journal of Obstetrics and Gynecology, 2011
- Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussisJournal of Clinical Microbiology, 2010
- What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratoriesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Tetanus toxoid immunization to reduce mortality from neonatal tetanusInternational Journal of Epidemiology, 2010
- Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive studyThe Lancet, 2007